Quanta Pharma Retatrutide 50mg + Free BW
Quanta Pharma Retatrutide 50mg + Free BW
In short 产品简述
New! Now in a 10ml Vial!
Quanta Pharma Retatrutide 50mg is a triple agonist that activates the GLP-1, GIP, and glucagon receptors. It enhances insulin secretion, increases energy expenditure, and reduces appetite, resulting in significant improvements in weight loss and metabolic regulation. Lab verified 99.84% purity.
Specifications 规格参数
About the Product 产品详情
NEW
Now Shipping in 10ml Vials
Quanta 50mg Retatrutide has been upgraded to a
larger 10ml vial format
, giving more headroom for reconstitution and easier, more flexible dosing.
LAB VERIFICATION – v7 DARK BRAND ALIGNED
border-bottom-color: rgba(124, 201, 236, 0.8);
Why not try our SerenQ Retatrutide Pens?
Pre-mixed and ready to use, no reconstitution needed 🔥 Currently on sale!
20mg – £140
40mg – £210
Included Free
+ 3ml Bacteriostatic Water with order
Independently Lab Verified
Three reports across two independent laboratories
Reports
Labs
99%+
Purity
Finished Product Test (Content + Purity)
New Just Tested
ANALIZA BIAŁEK
Actual Content
Label Claim
Purity
Sample:
Sealed lyophilised vial |
Order:
100016870 |
Method:
HPLC (BioBasic 8 Thermo Scientific) |
Verification Key:
F5J12Z9A
Tested 10 August 2026
Finished Product Test (Content + Purity)
ANALIZA BIAŁEK
Actual Content
Label Claim
Purity
Sample:
Sealed lyophilised vial |
Order:
100015226 |
Tested:
June 2026 |
Verification Key:
8U73BE1A
Independent Blind Screen
JANOSHIK
Actual Content
Label Claim
Purity
Sample:
Sealed lyophilised vial |
Method:
Blind Screen |
Tested:
September 2025 |
Verification Key:
RX4AKSZF838E
Quanta Pharma Retatrutide 50mg
is a pharmaceutical-grade
triple agonist peptide
targeting GLP-1, GIP, and glucagon receptors simultaneously. This lyophilised vial from
Quanta Pharma
offers researchers a high-purity compound for advanced metabolic and weight management studies. Independently verified across two laboratories: Analiza Białek confirmed 99% purity and 54.25mg content (August 2026), and Janoshik confirmed 99.84% purity (September 2025). Available for
UK delivery
with fast dispatch.
Quanta Pharma Retatrutide 50mg Specifications
Peptide
Retatrutide
Type
Triple Agonist
Dosage
50mg/vial
Purity
99%+
Form
Lyophilised
Half-Life
~6 Days
Retatrutide 50mg
Quanta Pharma
Quanta Pharma Retatrutide Research Benefits
Triple receptor action
Superior weight management
Enhanced fat oxidation
Glycemic control
Extended half-life
Dual lab verified
How Quanta Pharma Retatrutide Works
Quanta Pharma Retatrutide
is a
triple agonist peptide
that simultaneously activates three key receptors involved in metabolic regulation: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the Glucagon receptor. This unique triple-action approach sets it apart from all other incretin-based peptides.
The GLP-1 and GIP receptor activation enhances insulin secretion, reduces appetite, and slows gastric emptying. The addition of Glucagon receptor agonism is what makes
Quanta Pharma Retatrutide
truly unique, as it directly stimulates fat oxidation, increases energy expenditure, and promotes hepatic fat reduction. This three-pronged approach delivers superior metabolic effects in research settings.
Quanta Pharma Retatrutide vs Tirzepatide vs Semaglutide
Semaglutide
targets only the GLP-1 receptor.
Tirzepatide
activates both GLP-1 and GIP receptors.
Quanta Pharma Retatrutide
goes further by targeting all three receptors: GLP-1, GIP, and Glucagon. Clinical research has demonstrated that this triple agonist approach produces the most significant weight reduction results of any incretin-based compound studied to date, making
Quanta Pharma Retatrutide
the most advanced option for metabolic research.
Why Choose Quanta Pharma Retatrutide?
Quanta Pharma
is renowned for producing pharmaceutical-grade peptides with exceptional purity and accurate dosing. Each vial of
Quanta Pharma Retatrutide
undergoes rigorous quality control and is independently verified across two laboratories. Analiza Białek confirmed 99% purity with 54.25mg content in August 2026, and Janoshik’s blind screen confirmed 99.84% purity with 62.40mg content in September 2025. Both tests confirm overfilled vials that deliver more than the 50mg label claim.
⚠️ FOR LABORATORY RESEARCH USE ONLY
NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE
Safety Classification:
Legal Notice:
This product is exclusively intended for in vitro laboratory research conducted in controlled environments by qualified research staff. It is not for pharmaceutical, domestic, or any other applications. The purchaser accepts that acquiring and using this material is governed by all relevant UK regulations concerning research chemicals.
Third-Party Testing 第三方检测
What's in the Box 包装清单
- 1 x lyophilized powder vial (aluminum crimp cap + butyl stopper). Vial label carries batch number and expiry date.
Usage 使用说明
- Reconstitute with sterile or bacteriostatic water per the research protocol. Swirl gently after reconstitution; avoid vigorous shaking. Disinfect the stopper before withdrawing a dose.
Handling & Storage 储存条件
- Unreconstituted: refrigerate at 2-8 C, protect from light. Do not freeze; avoid repeated freeze-thaw cycles. Use within the supplier-stated period after reconstitution.
Applications 应用方向
For research purposes only 免责声明
Information on this entry is compiled from the public sales page (The Ped Shop) and is for research and reference only. Listed products are shown for research use, not sold as drugs or dietary supplements, and are not intended to diagnose, treat, cure or prevent any disease. Actual specification, price and stock are subject to the supplier page.